MCID: GLS001
MIFTS: 55

Gliosarcoma malady

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Gliosarcoma

Aliases & Descriptions for Gliosarcoma:

Name: Gliosarcoma 12 50 56 52 42 14 69
Glioblastoma with Sarcomatous Component 12
Sarcomatous Glioblastoma 50

Characteristics:

Orphanet epidemiological data:

56
gliosarcoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3071
MeSH 42 D018316
NCIt 47 C3796
Orphanet 56 ORPHA251576
ICD10 via Orphanet 34 G71.9
UMLS via Orphanet 70 C0206726
UMLS 69 C0206726

Summaries for Gliosarcoma

MalaCards based summary : Gliosarcoma, also known as glioblastoma with sarcomatous component, is related to adult brainstem gliosarcoma and liver fibrosarcoma, and has symptoms including headache and seizures. An important gene associated with Gliosarcoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are ERK Signaling and Glioma. The drugs Carmustine and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and smooth muscle, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 71 Gliosarcoma is a rare type of glioma, a cancer of the brain that comes from glial, or supportive, brain... more...

Related Diseases for Gliosarcoma

Diseases related to Gliosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 98)
id Related Disease Score Top Affiliating Genes
1 adult brainstem gliosarcoma 33.4 GFAP NES TP53
2 liver fibrosarcoma 10.4 GFAP TP53
3 cervical adenoid cystic carcinoma 10.4 GFAP TP53
4 brain stem astrocytic neoplasm 10.4 GFAP MGMT TP53
5 hypothalamic neoplasm 10.4 GFAP NES
6 middle ear disease 10.4 GFAP IDH1 TP53
7 vulvar benign neoplasm 10.4 GFAP NES TP53
8 brain oligodendroglioma 10.4 GFAP IDH1 TP53
9 adenofibroma 10.4 GFAP IDH1 NES
10 childhood central nervous system primitive neuroectodermal neoplasm 10.4 GFAP IDH1 TP53
11 angiofollicular lymph hyperplasia 10.4 GFAP NES
12 papillary tumor of the pineal region 10.4 GFAP IDH1
13 inner ear cancer 10.4 GFAP NES TP53
14 amyloid tumor 10.4 GFAP IDH1 MGMT TP53
15 central nervous system hemangioma 10.4 GFAP NES TP53
16 cutaneous adenocystic carcinoma 10.4 GFAP IDH1 MGMT TP53
17 ophn1 syndrome 10.4 GFAP MGMT
18 extraocular retinoblastoma 10.4 CCND3 RB1 TP53
19 wolffian adnexal neoplasm 10.3 EGFR TP53
20 myxedema 10.3 EGFR PTEN TP53
21 integumentary system benign neoplasm 10.3 CCND3 RB1 TP53
22 sengers syndrome 10.3 EGFR GFAP PTEN
23 papillary transitional carcinoma 10.3 FGFR3 RB1 TP53
24 pharynx cancer 10.3 GFAP LZTR1 TP53
25 epimetaphyseal dysplasia cataract 10.3 EGFR GFAP MGMT NES
26 nasopharyngeal carcinoma 10.3 EGFR IDH1 PTEN TP53
27 post-surgical hypoinsulinemia 10.3 CCND3 RB1 TP53
28 fallopian tube benign neoplasm 10.3 EGFR GFAP MGMT NES TP53
29 glucosephosphate isomerase deficiency 10.3 EGFR IDH1 PTEN TP53
30 paternal uniparental disomy of chromosome 1 10.3 EGFR GFAP IDH1 NES TP53
31 interstitial lung disease 10.3 EGFR GFAP MGMT PTEN TP53
32 marginal zone b-cell lymphoma 10.3 EGFR GFAP MGMT PTEN TP53
33 hypogonadotropic hypogonadism 20 with or without anosmia 10.3 EGFR PTEN RB1 TP53
34 glucose-6-phosphate translocase deficiency 10.3 EGFR MGMT PTEN RB1 TP53
35 prostatic adenoma 10.2 EGFR PTEN TP53
36 glioblastoma 10.2
37 ovarian epithelial cancer 10.2 FGFR1 FGFR3 NES
38 glomeruloid hemangioma 10.2 FGFR1 GFAP IDH1 MGMT PTEN
39 adult oligodendroglioma 10.2 EGFR GFAP IDH1 MGMT PTEN TP53
40 malignant pleural solitary fibrous tumor 10.2 EGFR GFAP IDH1 MGMT PTEN TP53
41 nodular goiter 10.2 EGFR GFAP MGMT NES PTEN TP53
42 neurilemmoma 10.2 FGFR1 IDH1
43 childhood embryonal testis carcinoma 10.2 EGFR GFAP IDH1 NES PTEN TP53
44 prostate cancer, hereditary, x-linked 1 10.2 FGFR3 PTEN TP53
45 autonomic nervous system neoplasm 10.2 EGFR FGFR3 PTEN RB1 TP53
46 ladd syndrome 10.2 EGFR FGFR3 RB1 TP53
47 lower lip cancer 10.2 EGFR PPARG PTEN
48 placenta praevia 10.2 EGFR FGFR3 RB1 TACC3 TP53
49 cerebritis 10.2
50 testis refractory cancer 10.2 IDH1 TP53

Graphical network of the top 20 diseases related to Gliosarcoma:



Diseases related to Gliosarcoma

Symptoms & Phenotypes for Gliosarcoma

UMLS symptoms related to Gliosarcoma:


headache, seizures

MGI Mouse Phenotypes related to Gliosarcoma:

44 (show all 24)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.43 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
2 homeostasis/metabolism MP:0005376 10.4 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1
3 mortality/aging MP:0010768 10.4 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP
4 hematopoietic system MP:0005397 10.38 PTEN CCND3 EGFR FGFR1 FGFR3 IDH1
5 immune system MP:0005387 10.36 NFKBIA PPARG PTEN RB1 SNAI2 TACC3
6 endocrine/exocrine gland MP:0005379 10.33 RB1 SNAI2 TACC3 TP53 CCND3 EGFR
7 cardiovascular system MP:0005385 10.32 GFAP PPARG PTEN RB1 SNAI2 TP53
8 embryo MP:0005380 10.25 EGFR FGFR1 FREM2 PPARG PTEN RB1
9 integument MP:0010771 10.24 EGFR FGFR1 FGFR3 FREM2 NFKBIA PPARG
10 craniofacial MP:0005382 10.21 FGFR1 FGFR3 FREM2 RB1 SNAI2 TACC3
11 digestive/alimentary MP:0005381 10.21 EGFR FGFR1 FGFR3 GFAP PTEN RB1
12 normal MP:0002873 10.14 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
13 limbs/digits/tail MP:0005371 10.13 EGFR FGFR1 FGFR3 FREM2 PTEN RB1
14 hearing/vestibular/ear MP:0005377 10.12 EGFR FGFR1 FGFR3 FREM2 PPARG RB1
15 neoplasm MP:0002006 10.11 CCND3 EGFR FGFR3 MGMT PPARG PTEN
16 muscle MP:0005369 10.08 EGFR FGFR1 FREM2 GFAP PPARG PTEN
17 liver/biliary system MP:0005370 10.05 EGFR PPARG PTEN RB1 TACC3 TP53
18 no phenotypic analysis MP:0003012 9.98 TP53 EGFR FGFR1 FGFR3 MGMT PPARG
19 renal/urinary system MP:0005367 9.92 EGFR FGFR1 FGFR3 FREM2 PPARG PTEN
20 reproductive system MP:0005389 9.91 EGFR FGFR1 FGFR3 FREM2 PPARG PTEN
21 pigmentation MP:0001186 9.85 EGFR FREM2 PTEN RB1 SNAI2 TP53
22 respiratory system MP:0005388 9.81 IDH1 MGMT PTEN RB1 TP53 CCND3
23 skeleton MP:0005390 9.7 EGFR FGFR1 FGFR3 FREM2 IDH1 PPARG
24 vision/eye MP:0005391 9.36 CCND3 EGFR FGFR1 FGFR3 FREM2 GFAP

Drugs & Therapeutics for Gliosarcoma

Drugs for Gliosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 400)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved Phase 3,Phase 2,Phase 1 154-93-8 2578
2
Lomustine Approved Phase 3,Phase 1 13010-47-4 3950
3
Procarbazine Approved Phase 3,Phase 1,Phase 2 671-16-9 4915
4
Trioxsalen Approved Phase 3,Phase 1 3902-71-4 5585
5
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
6
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
7
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
8
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
9
Vincristine Approved, Investigational Phase 3,Phase 1,Phase 2 2068-78-2, 57-22-7 5978
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
12
Morphine Approved, Investigational Phase 3 57-27-2 5288826
13
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
14
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
15
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5538 5282379
16
Dopamine Approved Phase 3,Phase 1 51-61-6, 62-31-7 681
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
19
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538
20
Veliparib Investigational Phase 2, Phase 3,Phase 1 912444-00-9 11960529
21 Alkylating Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
23 Dermatologic Agents Phase 3,Phase 1,Phase 2
24 Dihematoporphyrin Ether Phase 3,Phase 1
25 Ether Phase 3
26 Photosensitizing Agents Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 3,Phase 1,Phase 2
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
30 Antimitotic Agents Phase 3,Phase 1,Phase 2
31 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
32 Analgesics Phase 3,Phase 2,Phase 1
33 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
34 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
35 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
36 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
37 Keratolytic Agents Phase 3,Phase 1,Phase 2
38 O(6)-benzylguanine Phase 3,Phase 2,Phase 1
39 Anesthetics Phase 3,Phase 1
40 Anesthetics, General Phase 3
41 Anesthetics, Inhalation Phase 3
42 Hematoporphyrin Derivative Phase 3
43 Hematoporphyrins Phase 3
44 Adjuvants, Anesthesia Phase 3
45 Analgesics, Opioid Phase 3
46 Anesthetics, Intravenous Phase 3
47 Liver Extracts Phase 3,Phase 2,Phase 1
48 Narcotics Phase 3
49 pancreatic polypeptide Phase 3,Phase 1
50 Epoetin alfa Phase 3 113427-24-0

Interventional clinical trials:

(show top 50) (show all 461)
id Name Status NCT ID Phase
1 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3
2 S0001 RT and Carmustine With or Without O6BG in Patients With New Glioblastoma Multiforme or Gliosarcoma Completed NCT00017147 Phase 3
3 Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma Completed NCT00304031 Phase 3
4 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3
5 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3
6 Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00482677 Phase 3
7 Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00006353 Phase 3
8 Radiation Therapy Plus Chemotherapy in Treating Patients With Supratentorial Glioblastoma Multiforme Completed NCT00002545 Phase 3
9 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
10 SU-101 Compared With Procarbazine in Treating Patients With Glioblastoma Multiforme Completed NCT00003293 Phase 3
11 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3
12 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
14 E-MOSAIC Electronic Tool to Monitor Symptoms Completed NCT00477919 Phase 3
15 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3
16 Temozolomide (TMZ) and Radiation Therapy (RT) With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Active, not recruiting NCT00884741 Phase 3
17 VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM Not yet recruiting NCT03149575 Phase 3
18 Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Suspended NCT02152982 Phase 2, Phase 3
19 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
20 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3
21 Procarbazine and Isotretinoin in Treating Patients With Recurrent Primary Malignant Gliomas Withdrawn NCT00003564 Phase 3
22 Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma Unknown status NCT01124539 Phase 2
23 Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma Unknown status NCT00936052 Phase 2
24 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
25 Hydroxychloroquine, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00486603 Phase 1, Phase 2
26 Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00006460 Phase 1, Phase 2
27 Antineoplaston Therapy in Treating Patients With Glioblastoma Multiforme Unknown status NCT00003456 Phase 2
28 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2
29 Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Unknown status NCT00492687 Phase 2
30 Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme Unknown status NCT00054496 Phase 2
31 Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Unknown status NCT00047294 Phase 2
32 Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme Unknown status NCT00014105 Phase 1, Phase 2
33 Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Unknown status NCT00006656 Phase 2
34 Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma Unknown status NCT00045110 Phase 1, Phase 2
35 Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma Unknown status NCT00003176 Phase 2
36 A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2
37 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Unknown status NCT01026493 Phase 1, Phase 2
38 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma Unknown status NCT00047281 Phase 2
39 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2
40 Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma Completed NCT00525525 Phase 2
41 Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas Completed NCT00612339 Phase 2
42 Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma Completed NCT00335764 Phase 1, Phase 2
43 Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas Completed NCT00597402 Phase 2
44 Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed NCT00402116 Phase 1, Phase 2
45 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed NCT00187486 Phase 2
46 Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma Completed NCT00433381 Phase 2
47 Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Completed NCT00305864 Phase 1, Phase 2
48 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed NCT00979017 Phase 2
49 Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT00165477 Phase 2
50 Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme Completed NCT00883298 Phase 2

Search NIH Clinical Center for Gliosarcoma

Cochrane evidence based reviews: gliosarcoma

Genetic Tests for Gliosarcoma

Anatomical Context for Gliosarcoma

MalaCards organs/tissues related to Gliosarcoma:

39
Brain, Spinal Cord, Smooth Muscle, Bone, Pineal, Temporal Lobe, Parietal Lobe

Publications for Gliosarcoma

Articles related to Gliosarcoma:

(show top 50) (show all 349)
id Title Authors Year
1
An IDH1-mutated primary gliosarcoma: case report. ( 27153165 )
2016
2
Gliosarcoma: A rare variant of glioblastoma multiforme in paediatric patient: Case report and review of literature. ( 27672648 )
2016
3
Post-Treatment Gliosarcoma Extension into the Pterygomaxillary Fossa: Literature Review and Case Report. ( 27699141 )
2016
4
Gliosarcoma in the Cerebellopontine Angle with Rapid Tumor Growth and Intratumoral Hemorrhage. ( 27338213 )
2016
5
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27231756 )
2016
6
A Stable Secondary Gliosarcoma with Extensive Systemic Metastases: A Case Report. ( 27867925 )
2016
7
Gliosarcoma with smooth muscle cell differentiation: a case report. ( 27704522 )
2016
8
Brain tumors in Li-Fraumeni syndrome: a commentary and a case of a gliosarcoma patient. ( 27523101 )
2016
9
Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. ( 27792048 )
2016
10
Gliosarcomas lack BRAF(V600E) mutation, but a subset exhibit I^-catenin nuclear localization. ( 26932501 )
2016
11
Gliosarcoma with a primitive neuroectodermal tumour component. ( 27772848 )
2016
12
Primary Multifocal Gliosarcoma of the Spinal Cord. ( 27134708 )
2016
13
Evolution of DNA aptamers for malignant brain tumor gliosarcoma cell recognition and clinical tissue imaging. ( 26802746 )
2016
14
Prognostic and therapeutic factors of gliosarcoma from a multi-institutional series. ( 27169763 )
2016
15
Evaluation of Antitumor Activity of Long-Circulating and pH-Sensitive Liposomes Containing Ursolic Acid in Animal Models of Breast Tumor and Gliosarcoma. ( 27130721 )
2016
16
Radiotherapy plus concomitant temozolomide in primary gliosarcoma. ( 27025857 )
2016
17
Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients. ( 26725096 )
2016
18
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. ( 27314913 )
2016
19
Metastatic Gliosarcoma: Cytopathologic Characteristics with Histopathologic Correlations. ( 27584833 )
2016
20
Concurrent Gliosarcoma and Choroid Plexus Carcinoma in a Cow. ( 27899174 )
2016
21
Dural and osteolytic sarcomatoid relapse of a secondary gliosarcoma with tryptase immunoreactivity. ( 26784965 )
2016
22
Temporal Lobe Gliosarcoma After Gamma Knife Radiosurgery for Vestibular Schwannoma. ( 27309712 )
2016
23
Gliosarcoma with Primary Skull Base Invasion. ( 28053799 )
2016
24
Long-term survival in gliosarcoma with radiation-induced meningeal sarcomas: Case report and molecular features. ( 26458625 )
2015
25
Cerebral gliosarcoma: Analysis of 16 patients and review of literature. ( 26396606 )
2015
26
Pediatric gliosarcoma treated with adjuvant radiotherapy and temozolomide. ( 26438548 )
2015
27
Clinical outcome of patients with primary gliosarcoma treated with concomitant and adjuvant temozolomide: A single institutional analysis of 27 cases. ( 26960490 )
2015
28
Assessing Amide Proton Transfer (APT) MRI Contrast Origins in 9A L Gliosarcoma in the Rat Brain Using Proteomic Analysis. ( 25622812 )
2015
29
Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. ( 25839013 )
2015
30
Primary and secondary gliosarcomas: clinical, molecular and survival characteristics. ( 26354773 )
2015
31
Giant parietal lobe infantile gliosarcoma in a 5-year-old child. ( 26167224 )
2015
32
Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line. ( 25539862 )
2015
33
Gliosarcoma with primitive neuroectodermal, osseous, cartilage and adipocyte differentiation: a case report. ( 25973108 )
2015
34
Gliosarcoma with neuroaxis metastases. ( 26621904 )
2015
35
Gliosarcoma with leiomyomatous differentiation: A case report with an emphasis on histogenesis. ( 26881542 )
2015
36
Brachium Pontis Gliosarcoma With Well-Differentiated Cartilaginous Tissue: A Case Report. ( 26496287 )
2015
37
FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. ( 26279698 )
2015
38
Genetic alterations in gliosarcoma and giant cell glioblastoma. ( 26443480 )
2015
39
Primary Cerebellar Gliosarcoma with Extracranial Metastases: An Orphan Differential Diagnosis. ( 26239018 )
2015
40
An individual patient data meta-analysis on characteristics, treatments and outcomes of glioblastoma/ gliosarcoma patients with metastases outside of the central nervous system. ( 25860797 )
2015
41
Therapeutic management of gliosarcoma in the temozolomide era. ( 25905568 )
2015
42
An individual patient data meta-analysis on characteristics, treatments and outcomes of the glioblastoma/gliosarcoma patients with central nervous system metastases reported in literature until 2013. ( 25160993 )
2014
43
Sarcomatoid carcinoma of the jejunum presenting as obscure gastrointestinal bleeding in a patient with a history of gliosarcoma. ( 24759341 )
2014
44
Malignant pediatric gliosarcoma defies general survival data. ( 25580128 )
2014
45
Gliosarcoma occurrence after surgical clipping of aneurysm - coincidence or causal relationship? ( 24831372 )
2014
46
Recurrent gliosarcoma in pregnancy. ( 24900931 )
2014
47
Genetic and pathologic evolution of early secondary gliosarcoma. ( 23324827 )
2014
48
Primary gliosarcoma with long-survival: report of two cases and review of literature. ( 25337286 )
2014
49
A Phase III study of radiation therapy (RT) and O(6)-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. ( 25407559 )
2014
50
Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. ( 25065849 )
2014

Variations for Gliosarcoma

Cosmic variations for Gliosarcoma:

9
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10648 TP53 central nervous system,brain,glioma,gliosarcoma c.524G>A p.R175H 5
2 COSM5033 PTEN central nervous system,brain,glioma,gliosarcoma c.389G>A p.R130Q 5
3 COSM5123 PTEN central nervous system,brain,glioma,gliosarcoma c.395G>A p.G132D 5
4 COSM5154 PTEN central nervous system,brain,glioma,gliosarcoma c.697C>T p.R233* 5
5 COSM5152 PTEN central nervous system,brain,glioma,gliosarcoma c.388C>T p.R130* 5
6 COSM5191 PTEN central nervous system,brain,glioma,gliosarcoma c.198G>T p.K66N 5
7 COSM5308 PTEN central nervous system,brain,glioma,gliosarcoma c.565A>T p.R189* 5
8 COSM22413 PDGFRA central nervous system,brain,glioma,gliosarcoma c.2472C>T p.V824V 5
9 COSM564 NRAS central nervous system,brain,glioma,gliosarcoma c.35G>A p.G12D 5
10 COSM476 BRAF central nervous system,brain,glioma,gliosarcoma c.1799T>A p.V600E 5

Expression for Gliosarcoma

Search GEO for disease gene expression data for Gliosarcoma.

Pathways for Gliosarcoma

Pathways related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 CCND3 EGFR FGFR1 FGFR3 GFAP NFKBIA
2
Show member pathways
12.91 EGFR FGFR1 FGFR3 NFKBIA PTEN RB1
3
Show member pathways
12.61 EGFR FGFR1 FGFR3 NFKBIA PTEN TP53
4
Show member pathways
12.43 EGFR FGFR1 FGFR3 PTEN TP53
5 12.42 CCND3 MGMT RB1 TACC3 TP53
6 12.42 CCND3 EGFR FGFR1 FGFR3 PTEN TP53
7 12.36 CCND3 NFKBIA RB1 TP53
8
Show member pathways
12.36 EGFR FGFR1 FGFR3 NFKBIA TP53
9 12.35 EGFR FGFR1 FGFR3 NFKBIA PPARG PTEN
10
Show member pathways
12.33 CCND3 NFKBIA PTEN TP53
11
Show member pathways
12.3 CCND3 PTEN RB1 TP53
12 12.23 CCND3 NFKBIA RB1 TP53
13
Show member pathways
12.18 EGFR FGFR1 FGFR3 PTEN
14 12.09 EGFR PTEN RB1 TP53
15
Show member pathways
12.03 EGFR NFKBIA RB1 TP53
16 12.01 CCND3 MGMT PTEN TP53
17 11.93 EGFR GFAP RB1 TP53
18 11.89 EGFR PTEN RB1 SNAI2 TP53
19 11.83 FGFR1 FGFR3 GFAP SNAI2
20 11.79 EGFR PTEN RB1
21 11.77 CCND3 RB1 TP53
22 11.76 EGFR MGMT PTEN RB1 TP53
23
Show member pathways
11.71 CCND3 EGFR FGFR1 FGFR3 PTEN RB1
24 11.7 NFKBIA PTEN RB1 TP53
25 11.67 EGFR FGFR1 SNAI2
26 11.66 FGFR1 FGFR3 GFAP NES
27 11.6 EGFR FGFR3 RB1 TP53
28 11.5 EGFR RB1 TP53
29 11.45 PTEN RB1 TP53
30 11.43 EGFR FGFR1 FGFR3
31 11.41 CCND3 NFKBIA TP53
32 11.05 NFKBIA TACC1 TACC3 TP53
33 10.91 EGFR FGFR1 FGFR3 IDH1 PTEN TP53

GO Terms for Gliosarcoma

Cellular components related to Gliosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.5 CCND3 EGFR FGFR1 FGFR3 GFAP IDH1

Biological processes related to Gliosarcoma according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.93 CCND3 FGFR1 PPARG RB1 SNAI2 TP53
2 regulation of cell proliferation GO:0042127 9.8 CCND3 EGFR FGFR1 NFKBIA
3 cell division GO:0051301 9.8 CCND3 RB1 SEPT14 TACC1 TACC3
4 cell cycle GO:0007049 9.8 CCND3 RB1 SEPT14 TACC1 TACC3 TP53
5 cell proliferation GO:0008283 9.77 EGFR PTEN TACC1 TACC3 TP53
6 negative regulation of apoptotic process GO:0043066 9.73 EGFR MGMT NFKBIA PTEN SNAI2 TP53
7 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.69 EGFR FGFR1 FGFR3
8 negative regulation of telomerase activity GO:0051974 9.55 PPARG TP53
9 white fat cell differentiation GO:0050872 9.54 PPARG SNAI2
10 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.52 NFKBIA PPARG
11 salivary gland morphogenesis GO:0007435 9.48 EGFR FGFR1
12 positive regulation of phospholipase activity GO:0010518 9.43 FGFR1 FGFR3
13 response to organic cyclic compound GO:0014070 9.35 EGFR IDH1 MGMT PPARG PTEN
14 cellular response to ionizing radiation GO:0071479 9.33 MGMT SNAI2 TP53
15 phosphatidylinositol-mediated signaling GO:0048015 9.02 EGFR FGFR1 FGFR3 PTEN TP53

Molecular functions related to Gliosarcoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.54 EGFR PPARG TP53
2 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 EGFR FGFR1 FGFR3
3 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 EGFR FGFR1 FGFR3
4 enzyme binding GO:0019899 9.43 EGFR NFKBIA PPARG PTEN RB1 TP53
5 identical protein binding GO:0042802 9.23 EGFR FGFR1 GFAP NFKBIA PPARG PTEN
6 fibroblast growth factor-activated receptor activity GO:0005007 9.16 FGFR1 FGFR3

Sources for Gliosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....